医疗保险部分 D 下沙库巴曲缬沙坦的国家覆盖范围和自付费用评估。
Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D.
机构信息
Center for Healthcare Value, Philip R. Lee Institute for Health Policy Studies, Department of Medicine, University of California, San Francisco School of Medicine, San Francisco.
Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
出版信息
JAMA Cardiol. 2019 Aug 1;4(8):828-830. doi: 10.1001/jamacardio.2019.2223.
Abstract
This study examines the insurance coverage and out-of-pocket costs to Medicare beneficiaries for the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan.
摘要
本研究考察了 Medicare 受益人为血管紧张素受体-脑啡肽酶抑制剂沙库巴曲缬沙坦所支付的保险覆盖范围和自付费用。
相似文献
1
Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D.医疗保险部分 D 下沙库巴曲缬沙坦的国家覆盖范围和自付费用评估。
JAMA Cardiol. 2019 Aug 1;4(8):828-830. doi: 10.1001/jamacardio.2019.2223.
2
Sacubitril-Valsartan for the Treatment of Heart Failure: Effectiveness and Value.沙库巴曲缬沙坦治疗心力衰竭：有效性与价值
JAMA Intern Med. 2016 Feb;176(2):249-50. doi: 10.1001/jamainternmed.2015.7661.
3
What will be the impact of sacubitril/valsartan in clinical practice?沙库巴曲缬沙坦在临床实践中的影响将会是什么？
J Cardiovasc Med (Hagerstown). 2018 Feb;19 Suppl 1:e88-e90. doi: 10.2459/JCM.0000000000000568.
4
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure.当代医疗保险和医疗补助的使用模式及心力衰竭患者中沙库巴曲缬沙坦和伊伐布雷定的相关支出。
JAMA Cardiol. 2020 Mar 1;5(3):336-339. doi: 10.1001/jamacardio.2019.4982.
5
Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.沙库巴曲缬沙坦在心力衰竭管理中的应用。
Circ Heart Fail. 2018 Feb;11(2):e004302. doi: 10.1161/CIRCHEARTFAILURE.117.004302.
6
Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.沙库巴曲缬沙坦：心力衰竭指南导向药物治疗工具库中的最新药物。
Am J Med. 2017 Jun;130(6):635-639. doi: 10.1016/j.amjmed.2017.02.010. Epub 2017 Mar 9.
7
An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands.沙库巴曲缬沙坦用于荷兰心力衰竭患者的经济学评估
Value Health. 2017 Mar;20(3):388-396. doi: 10.1016/j.jval.2016.10.015. Epub 2016 Dec 22.
8
Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.沙库巴曲缬沙坦钠联合治疗与依那普利治疗射血分数降低的心力衰竭的成本效果比较。
JACC Heart Fail. 2016 May;4(5):392-402. doi: 10.1016/j.jchf.2016.02.007. Epub 2016 Mar 30.
9
Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany.沙库必曲缬沙坦（LCZ696）：一种用于心力衰竭的新型治疗方法，及其在德国的成本效果估计、预算影响和疾病负担减轻。
Pharmacoeconomics. 2018 Oct;36(10):1285-1296. doi: 10.1007/s40273-018-0688-4.
10
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.血管紧张素受体拮抗剂与中性内肽酶抑制剂联合使用
Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622.
引用本文的文献
1
Challenges Related to Out-of-Pocket Costs in Heart Failure Management.心力衰竭管理中与自付费用相关的挑战
Circ Heart Fail. 2025 Mar;18(3):e011584. doi: 10.1161/CIRCHEARTFAILURE.124.011584. Epub 2025 Feb 28.
2
Integrating Out-of-Pocket Costs Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Stepped-Wedge Trial (POCKET-COST-HF).将自付费用纳入射血分数降低的心力衰竭共同决策：一项阶梯楔形试验（POCKET-COST-HF）
Circ Cardiovasc Qual Outcomes. 2025 Jan;18(1):e011273. doi: 10.1161/CIRCOUTCOMES.124.011273. Epub 2024 Dec 3.
3
Industry marketing payments to physicians and prescription patterns for sacubitril/valsartan in the USA.美国医药行业向医生支付的营销费用以及沙库巴曲缬沙坦的处方模式。
Heart. 2025 Jan 29;111(4):147-150. doi: 10.1136/heartjnl-2024-324453.
4
Sacubitril-Valsartan in Patients Requiring Hemodialysis.沙库巴曲缬沙坦在需要血液透析的患者中的应用。
JAMA Netw Open. 2024 Aug 1;7(8):e2429237. doi: 10.1001/jamanetworkopen.2024.29237.
5
Integrating Cost into Shared Decision-Making for Heart Failure with Reduced Ejection Fraction (POCKET-COST-HF): A Trial Providing Out-of-Pocket Costs for Heart Failure Medications during Clinical Encounters.将费用纳入射血分数降低的心力衰竭的共同决策（POCKET-COST-HF）：一项在临床就诊期间提供心力衰竭药物自付费用的试验。
Am Heart J. 2024 Mar;269:84-93. doi: 10.1016/j.ahj.2023.11.013. Epub 2023 Dec 12.
6
DASH-HF Study: A Pragmatic Quality Improvement Randomized Implementation Trial for Patients With Heart Failure With Reduced Ejection Fraction.DASH-HF 研究：射血分数降低的心力衰竭患者的实用质量改进随机实施试验。
Circ Heart Fail. 2023 Sep;16(9):e010278. doi: 10.1161/CIRCHEARTFAILURE.122.010278. Epub 2023 Jul 26.
7
Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out-of-Pocket Costs.是否选择服用沙库巴曲缬沙坦：心内科医生和患者如何讨论自付费用。
J Am Heart Assoc. 2023 Apr 4;12(7):e028278. doi: 10.1161/JAHA.122.028278. Epub 2023 Mar 28.
8
A case study of recurrent myocardial infarction secondary to socioeconomic challenges and nonadherence: Pre-discharge screening.一例继发于社会经济挑战和不依从性的复发性心肌梗死病例研究：出院前筛查
SAGE Open Med Case Rep. 2023 Mar 21;11:2050313X231162921. doi: 10.1177/2050313X231162921. eCollection 2023.
9
Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction.网络荟萃分析比较血管紧张素受体-脑啡肽酶抑制剂、血管紧张素受体阻滞剂和血管紧张素转换酶抑制剂在射血分数降低的心力衰竭中的疗效。
Am J Cardiol. 2023 Jan 15;187:84-92. doi: 10.1016/j.amjcard.2022.10.026. Epub 2022 Nov 29.
10
Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure.抗血管紧张素受体脑啡肽酶抑制剂的费用分担额与心力衰竭患者药物填充之间的关联。
J Am Heart Assoc. 2022 Dec 20;11(24):e027662. doi: 10.1161/JAHA.122.027662. Epub 2022 Dec 1.
本文引用的文献
1
Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.沙库巴曲缬沙坦在心力衰竭管理中的应用。
Circ Heart Fail. 2018 Feb;11(2):e004302. doi: 10.1161/CIRCHEARTFAILURE.117.004302.
2
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.2016年美国心脏病学会/美国心脏协会/美国心力衰竭学会关于心力衰竭新药物治疗的重点更新：2013年美国心脏病学会基金会/美国心脏协会心力衰竭管理指南更新：美国心脏病学会/美国心脏协会临床实践指南特别工作组及美国心力衰竭学会的报告
Circulation. 2016 Sep 27;134(13):e282-93. doi: 10.1161/CIR.0000000000000435. Epub 2016 May 20.
3
Angiotensin-neprilysin inhibition versus enalapril in heart failure.血管紧张素-脑啡肽酶抑制剂与依那普利治疗心力衰竭的比较。
N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.
4
Full coverage for preventive medications after myocardial infarction.心肌梗死后的预防性药物全覆盖。
N Engl J Med. 2011 Dec 1;365(22):2088-97. doi: 10.1056/NEJMsa1107913. Epub 2011 Nov 14.
5
Epidemiology and risk profile of heart failure.心力衰竭的流行病学和风险特征。
Nat Rev Cardiol. 2011 Jan;8(1):30-41. doi: 10.1038/nrcardio.2010.165. Epub 2010 Nov 9.
Zotero 插件